Skip to main content

Adverum Biotechnologies, Inc. (ADVM)

NASDAQ: ADVM · IEX Real-Time Price · USD
1.97
+0.02 (1.03%)
After-hours:Oct 22, 2021 7:58 PM EDT
1.95
-0.05 (-2.50%)
At close: Oct 22, 4:00 PM
Market Cap196.25M
Revenue (ttm)7.50M
Net Income (ttm)-138.17M
Shares Out98.02M
EPS (ttm)-1.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,334,836
Open2.00
Previous Close2.00
Day's Range1.92 - 2.00
52-Week Range1.92 - 14.79
Beta1.18
AnalystsBuy
Price Target3.67 (+88.2%)
Est. Earnings DateNov 4, 2021

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was ...

IndustryBiotechnology
IPO DateJul 31, 2014
CEOLeone Patterson
Employees167
Stock ExchangeNASDAQ
Ticker SymbolADVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 88.21% from the latest price.

Price Target
$3.67
(88.21% upside)
Analyst Consensus: Buy

News

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Other symbols:ABUSADTXENVBEVFM
1 week ago - PennyStocks

Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --

1 week ago - GlobeNewsWire

Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD). Data were shared ...

2 weeks ago - Benzinga

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:ABUSKLDOMNKDTRVN
2 weeks ago - PennyStocks

Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intrav...

-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --

3 weeks ago - GlobeNewsWire

Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences

REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...

3 weeks ago - GlobeNewsWire

Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

1 month ago - GlobeNewsWire

Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

-- Based on latest analyses, company is revising ADVM-022 development plan to focus on  wet AMD and low doses (2 x 10^11 vg/eye and lower);  no longer planning development for DME -- -- Company to host ...

3 months ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

Adverum Announces Changes to Management Team

-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --

3 months ago - GlobeNewsWire

A Trio of Net Current Asset Value Stock Picks

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...

Other symbols:CLBSIFRX
4 months ago - GuruFocus

Why Adverum Biotechnologies Stock Sank in May

The uncertainty over the biotech's lead clinical asset weighed on its shares last month.

4 months ago - The Motley Fool

Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?

Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?

Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

5 months ago - Zacks Investment Research

Goldman Sachs Has 5 Tempting Stocks Trading Under $10 to Buy Now

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:ADTINFNKOSSWN
5 months ago - 24/7 Wall Street

The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

5 months ago - Business Wire

Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...

5 months ago - GlobeNewsWire

The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

5 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM

NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advi...

5 months ago - PRNewsWire

The Sonic Fund II, L.P. Reminds Adverum Stockholders to Vote for Its Three Independent Director Nominees at May 12 An...

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

5 months ago - Business Wire

Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...

5 months ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Adverum Reports First Quarter 2021 Results

REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...

5 months ago - GlobeNewsWire

2 Falling Knives to Catch

Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...

Other symbols:AKBA
5 months ago - GuruFocus